NCT01710020View on ClinicalTrials.gov

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
End-Stage Renal DiseaseHemodialysis
Interventions
DRUG

CP-690,550

CP-690,550 10 mg oral powder for constitution

Trial Locations (2)

32806

Pfizer Investigational Site, Orlando

55404

Pfizer Investigational Site, Minneapolis

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY